Background: Previous reports identifying discordance between multiparameter tests at the
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Conclusions:
Existing evidence on the comparative prognostic information provided by different tests suggests current multiparameter tests provide broadly equivalent risk information for the population of women with estrogen receptor (ER)-positive breast cancers. However, for the individual patient, tests may provide differing risk categorisation and subtype information.
INTRODUCTION
For over 40 years (1-3) the impact of tumour molecular markers on patient outcome and treatment response has been central to breast cancer management. 5) to describe the intrinsic subtypes of breast cancer was followed by the independent development, in 2004, of the first multiparameter molecular diagnostic assay stratifying breast cancer patients with estrogen receptor (ER) positive disease based on risk of relapse following treatment (6). The past decade saw a rapid expansion in the number of such multiparameter molecular residual risk tests for breast cancer patients (see (7)). These herald an era of more personalised medicine because of their potential to inform rational treatment decisions on a patient-by-patient basis. The initial goal was to identify patients who, despite "favourable" clinico-pathological characteristics, have a poor outcome following conventional endocrine treatment and to advise aggressive therapy, which may reduce relapse risk. Over time, interest has also grown in the potential for multiparameter assays to predict chemo-sensitivity (8;9). These tests may also allow an estimate of the intrinsic chemotherapy sensitivity of tumours, reducing the importance of stage information. There are women who gain little from chemotherapy and women who have clinically relevant gains. There is therefore a rationale for using stratified medicine to identify patients who may safely avoid toxicities associated with chemotherapy.
The OPTIMA trial (7) is designed as a prospective test of the effectiveness of multiparameter testing in identifying the sub-group of women with breast cancer (among those who would be routinely offered adjuvant chemotherapy based on conventional criteria) whose tumours are intrinsically insensitive to chemotherapy and for whom such treatment offers only toxicity and delay in starting more effective adjuvant endocrine therapy and radiotherapy without any clinically meaningful additional benefit. A key objective of "OPTIMA prelim", the in-built feasibility phase of OPTIMA, was to evaluate the performance of alternative multiparameter tests, to aid selection of a test for 6
Manuscript submitted 17 February 2016 -FINAL the main study that would ensure the results of such a trial be robust and broadly applicable to the patient population, both now and in the future. Critical to this decision was the ability to compare test performance at both the population and individual patient level. Existing data directly comparing individual test performance is limited. A series of studies performing statistical comparisons between tests suggest that, at a population level, four tests (IHC4, PAM50, BCI and Oncotype DX) provided broadly equivalent prognostic information on the risk of relapse up to five years post treatment (10) (11) (12) . Further studies, based largely on in silico reconstruction of existing tests from publically available gene expression datasets suggest a statistically significant degree of discordance between signatures at the individual patient level (13) (14) (15) (16) (17) . These observations are predominantly attributed to methodological differences due the in silico reconstruction of signatures (15;17) . This thesis has not, to date, been robustly tested using actual test methodologies. Limited data shows that concordance between different tests in assigning patients to similar risk groups is low (10). This is consistent with the marked differences in genes measured by different tests (See Supplementary Table 1 , available online) and with the relatively modest predictive value, in terms of recurrence, offered by these tests at the individual patient level. Here we report the direct patient-level comparison of multiple commercial residual risk profiles in the OPTIMA prelim study, performed to gather information on their performance.
MATERIALS AND METHODS
Recruitment and patient samples
Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis preliminary study (OPTIMA prelim, ISRCTN42400492) (18) is a multicentre study that randomly assigned women aged ≥40 with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer and either one to nine involved axillary nodes or tumour size of 30mm or 7
Manuscript submitted 17 February 2016 -FINAL greater (if node-negative) between standard treatment (chemotherapy followed by endocrine therapy) and test-directed therapy (7). In the test-directed arm an Oncotype DX test was performed; patients with Recurrence Scores (RSs) greater than 25 ("high" risk) were assigned chemotherapy followed by endocrine therapy, those with RSs of 25 or lower ("intermediate/low" risk) received endocrine therapy alone. Chemotherapy, selected from regimens commonly used in the UK NHS, was specified at patient registration. The study was partially blinded so that neither patients nor referring centres were aware of whether chemotherapy was assigned on the basis of Oncotype DX RS or by random assignment to the standard treatment arm. Central retesting of ER and HER2 status was performed on all patients.
Following confirmation of eligibility, samples were sent to Genomic Health for Oncotype DX assays to be performed with funding from the OPTIMA prelim study. No patient outcome data is available for this analysis. All patients gave written informed consent to participate in the study. The study was approved by the South East Coast -Surrey Research Ethics Committee. 
Statistical Analysis
OPTIMA prelim was designed to recruit 300 patients to enable the kappa value for agreement between tests to be estimated with good accuracy. Assuming 70% of patients would be assigned to no chemotherapy by the test and the true kappa value was 0·8 (14), this would provide a lower 95% confidence limit of 0·73. These numbers were also sufficient to allow for the assumed proportion of patients assigned to no chemotherapy to vary from 55% to 80% (lower confidence limit for kappa varied from 0·74 to 0·72 respectively).
The proportion of tumours assigned to risk groups and/or subtypes was determined. The kappa coefficient and associated 95% (CI) was used to assess agreement between tests. The predicted benefits of endocrine therapy with or without chemotherapy individualised to patients were estimated using two nomograms, Adjuvant! (20) (version 8, without correction for HER2 status) and . A multivariable logistic regression model using stepwise elimination was performed to determine factors predicting discordant cases. To explore the post hoc hypothesis that individual tests were more likely to agree at the extremes of their ranges, twoby-two scatterplots for the tests that provide risks scores and agreement charts for the categorisation of tumours were constructed (24). Statistical analyses were performed using the SAS statistical package (version 9.3; SAS Institute Inc., Cary, NC) and R version 3·0·3 (25). All statistical tests were two-sided and a p-value of less than 0.05 was considered statistical significant.
RESULTS
Patients
Between October 2012 and June 2014, 313 patients were randomly assigned from 35 UK hospitals (see the Notes), of whom 302 had samples available for multiparameter testing (Table   1 ). Eleven patients were excluded from multiparameter testing; four withdrew consent, one was ineligible and samples for six patients were insufficient for testing (Supplementary Figure 1, available online).
Results from predictive nomograms
The majority of patients recruited were either at intermediate (74.8%) or high (21.2%) risk using the Nottingham Prognostic Index (NPI) (26). All 12 patients with lower risk NPI scores (<3·4) had tumours 3·0 cm or larger in size. The median 10 year overall survival estimated by or Adjuvant! (20) differed by 6.2% to 8.4% reflecting expected differences between the risk estimate provided by these tools (Table 2) .
Multiparameter tests
Results from all tests were available for 236 (78.1%) patients. One patient on the standard arm had insufficient invasive tumour for Oncotype DX testing, but sufficient for alternative testing. However for 31.1% of tumours (n=94) agreement was observed in four of the five tests. There were also no clear differences between tests in terms of the agreement with other tests (Table 5) .
No statistically significant differences in clinico-pathological features between tumours that were concordant or discordant were observed (Supplementary Table 4 , available online). There is no evidence from the scatterplots of risk scores that individual tests were more likely to agree at the extremes of their ranges (Supplementary Figure 2, Tables 6-7, available online) again modest agreement between tests was observed.
Intrinsic Subtypes
The three tests that provide subtype information categorised similar proportions of patients as having "luminal A" tumours (BluePrint: 60.7%, 95% CI = 55.2% to 66.3%, Prosigna: 59.5%, 95% CI = 53.9% to 65.1% and MammaTyper (combined luminal A and low-risk luminal B):
62.4%, 95% CI = 56.9% to 67.9%). Thirteen (4.3%) patients were classified as having HER2 enriched/positive tumours by at least one test. Two (0.7%) patients had basal like tumours using Prosigna™ subtyping; one of whom also had a basal like tumour using BluePrint™ but triple negative breast cancer using MammaTyper™. All these patients were classified as ER-positive Assessing relationship between the Prosigna subtyping and risk of recurrence score
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Prosigna is unique amongst the multiparameter assays evaluated in providing both a subtype and a continuous risk of recurrence score (ROR) with predefined risk categories derived from an identical set of genes. All 178 tumours classified as luminal A had a ROR score below the predefined high risk cut-point, and none of the 113 luminal B tumours were classified as low-risk (Table 6) . Eight tumours, all of which were centrally confirmed as ER-positive/HER2-negative were categorised into either the basal-like (n=2) or HER2-like (n=6) subtypes and these were either intermediate or high risk by ROR score respectively.
DISCUSSION
The evaluation of candidate multiparameter tests within OPTIMA prelim to determine the best assessment of risk stratification for the main OPTIMA study presented an interesting challenge given: 1) Evidence that these tests provide broadly similar prognostic information at the population level (26); 2) The use of markedly different gene panels to estimate the same endpoint;
3) The use of different technologies including immunohistochemistry, polymerase chain reaction (PCR), quantitative and semi-quantitative array-based technologies.
Previous in silico comparisons of multiple gene signatures have identified statistically significant discordance between different "diagnostic tests" (13;15-17) . However, to date, this has been attributed to sub-optimal comparisons, since in the majority of studies genomic prediction scores have been estimated from published expression profiles. It has been argued that, in any direct comparison of validated diagnostic genomic assays, a high level of concordance could and should be obtained (14) . In the current study we performed such a direct comparison, each commercial assay was performed as prescribed by the relevant manufacturer (although the AQUA-IHC4 assay used TMAs for convenience). What is striking is that, amongst five tests with robust independent technical and clinical validation as predictors of residual risk (MammaPrint,
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Manuscript submitted 17 February 2016 -FINAL Oncotype DX, Prosigna, IHC4 and IHC4-AQUA) and three that measure a recognised risk factor (molecular subtype) there is marked disagreement across all tests. Indeed for all tests the level of agreement was "moderate" as defined by Prat et al, reaching only level 3 reproducibility (қ0.40-0.59) (14). This suggests that agreement for risk classification between different molecular tests applied to the same patient sample is on the level of agreement for pathological assessment of tumour grade.
The observed disagreement in risk categorisation for 60.6% of tumours raises questions as to how patient management may be impacted by the choice of test used for risk stratification.
Interestingly there does not seem to be better correlation between tests at the extremes of their ranges (the very low and high risk tumours in our cohort) than in the mid-range. It was less common, although not infrequent, for tumours placed into the lowest risk group by one test to be assigned into the highest risk group by another.
Each test is independently validated and adopted for prediction of risk of recurrence, so what should we do when they disagree? Paradoxically the result of this study can be viewed as either predictable or unexpected, depending on perspective. From a purely biological and technical perspective it is entirely predictable that tests which measure fundamentally different genes using From a clinical perspective the disagreement between multiple tests each assessing residual risk is highly perplexing. The disagreement extends to an inability to demonstrate strong agreement on molecular subtyping between tests, which again seems counter-intuitive. However, it is less surprising that disagreement between molecular subtyping, in this context predominantly between luminal A and luminal B, should exist in the absence of any clinical or molecular agreement as to the true boundary between a "luminal A" and "luminal B" cancer (16). Again, the Prosigna and BluePrint tests for subtyping have minimal gene overlap with only seven genes in common.
What about risk prediction? The prediction of disease recurrence based on clinicopathological and molecular features of a cancer is notoriously challenging within populations and even more so at the individual patient level. Biologically and clinically aggressive cancers which, if left untreated, are destined to progress may be "cured" by surgery, radiotherapy, chemotherapy or endocrine therapy. Tests predicting risk therefore face an important challenge in that they seek to measure both the risk of recurrence based on the biology of tumours and must function within a clinical setting where biology may reflect risk that is not realised due to medical intervention.
What then can we learn from comparisons between validated assays that seek to stratify patients by risk of recurrence, if indeed we can learn anything? We argue that there is value in such comparisons, even in the absence of outcome data. Each test applied in this study is externally validated and adopted or available for adoption in multiple clinical jurisdictions (6;27-32).
However none is, or claims to be, the ultimate discriminator of risk for patients. This study suggests there is more than one way of predicting residual risk.
All studies have limitations. While unable to determine subtle nuances in the performance of different tests within this population, we also recognise that existing data, both from the original data from OPTIMA prelim were available at the time of analysis. As the sample size is comparatively small it is highly unlikely that it will prove possible to compare the ability of the tests studied here to predict patient outcome.
In conclusion, in the widest and most comprehensive patient level direct diagnostic comparisons to date between multi-parametric tests of "residual risk" (after local treatment and endocrine therapy) we present further data that the proportions of patients identified as low, intermediate or high risk are broadly similar irrespective of which test is employed. However, both with respect to risk stratification and molecular sub-typing, marked differences were observed when categorisation of individual patients was considered. Such data, when considered with existing data on efficacy comparisons between different tests, support the conclusion that many current risk stratification tools are broadly equivalent and that further improvements in both prediction of relapse risk and therapeutic targeting would be of clinically significant value for patients at high risk of disease relapse (14). contributions to the concept and design of the study, its day-to-day management and overall conduct, data analysis and contributed to manuscript writing.
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